Mid-cap biotechs join Trump’s latest round of drug pricing deals

Mid-cap biotechs join Trump’s latest round of drug pricing deals is a pharma and life sciences industry update from Healthcare Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Jonathan Gardner · 2026-09-01

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies.

Source: Healthcare Dive